



Supplementary Material

Article Title: A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment

Author(s): John M. Kane, MD; Mary Mackle, PhD; Linda Snow-Adami, BS; Jun Zhao, PhD; Armin Szegedi, MD, PhD; and John Panagides, PhD

DOI Number: 10.4088/JCP.10m06306

List of Supplementary Material for the article

1. [eTable 1](#) Characteristics of Switched-Therapy Patients
2. [eTable 2](#) Mean \pm SD Changes in Laboratory Results From Baseline (Treated Population)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eTable 1. Characteristics of Switched-Therapy Patients*

	Number (%) of Patients			
	Open-Label Phase		Double-Blind Phase	
	Nonrandomized (n=235)	Randomized (n=313)	Asenapine (n=155)	Placebo (n=158)
Switched-therapy patients	548 (78.3) [†]			
Prior antipsychotics used by ≥5% of switched-therapy patients				
Risperidone	179 (25.6)			
Olanzapine	106 (15.1)			
Quetiapine	68 (9.7)			
Haloperidol	67 (9.6)			
Trifluoperazine	59 (8.4)			
Aripiprazole	39 (5.6)			
Discontinuations	235 (100.0)	–	45 (29.0)	102 (64.6)
Most common reasons for discontinuation				
Withdrawal of consent	83 (35.3)	–	15 (9.7)	9 (5.7)
AEs	73 (31.1)	–	10 (6.5)	43 (27.2)

AE=adverse event.

*Defined as switched from previous antipsychotic therapy to open-label treatment with asenapine.

[†]Based on open-label treated population (n=700).

eTable 2. Mean ± SD Changes in Laboratory Results From Baseline* (Treated Population)

	Open-Label Phase				Double-Blind Phase			
	Nonrandomized (n=314)		Randomized (n=386)		Asenapine (n=194)		Placebo (n=192)	
HbA _{1c} , %	0.11±0.50		0.09±0.47		0.05±0.40		-0.06±0.67	
AST, U/L	1.4±10.2		2.0±20.7		2.3±24.5		0.1±9.5	
ALT, U/L	0.1±16.4		3.7±34.8		-2.2±26.9		-2.0±14.8	
	mmol/L	mg/dL	mmol/L	mg/dL	mmol/L	mg/dL	mmol/L	mg/dL
Total cholesterol	-0.036±0.731	-1.39±28.2	-0.027±0.739	-1.04±28.5	0.024±0.718	0.927±27.7	-0.145±0.673	-5.60±26.0
HDL	-0.013±0.235	-0.502±9.07	-0.031±0.216	-1.20±8.34	0.005±0.214	0.193±8.26	0.006±0.212	0.232±8.19
LDL	-0.028±0.564	-1.08±21.8	0.023±0.568	0.888±21.9	-0.009±0.573	-0.347±22.1	-0.097±0.575	-3.75±22.2
Triglycerides [†]	-0.105±1.184	-9.29±104.8	0.042±0.785	3.72±69.5	0.010±0.995	0.885±88.1	-0.127±0.743	-11.2±65.8
Glucose [†]	0.302±1.633	5.44±29.4	0.159±1.146	2.86±20.6	0.116±1.480	2.09±26.7	0.001±1.146	0.018±20.6

AST=aspartate aminotransferase; ALT=alanine aminotransferase; HbA_{1c}=glycosylated hemoglobin; HDL=high-density lipoprotein; LDL=low-density lipoprotein.

*Data from open-label phase are changes from open-label phase baseline, and data from double-blind phase are changes from double-blind phase baseline.

[†]Triglycerides and glucose are based on fasting blood samples; all other results are based on randomly obtained samples.